Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M., McKay, Pamela, Leitch, Sophie, Coleman, Morton, Zinzani, Pier Luigi, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Browett, Peter, Ke, Xiaoyan, Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679804/
https://www.ncbi.nlm.nih.gov/pubmed/37682792
http://dx.doi.org/10.1182/bloodadvances.2023010668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679804/
https://www.ncbi.nlm.nih.gov/pubmed/37682792
http://dx.doi.org/10.1182/bloodadvances.2023010668

Ejemplares similares